A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984

Kallio, Merja; Sankila, Risto; Jääskeläinen, Juha E.; Karjalainen, Sakari; Hakulinen, Timo

doi:10.1002/1097-0142(19910915)68:6<1394::aid-cncr2820680636>3.0.co;2-8

Cited by 46 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Incidence in the north of England for an earlier time period gives a crude intermediate rate of 25.7 per million (Craft et al, 1987). The relative frequency of the diagnostic subgroups reflects the pattern of other population-based studies (Parkin et al, 1988a, Kallio et al, 1991. The diffculties associated with the ascertainment of brain tumours and the fact that analysis of validated data gives rise to increased rates, as shown by our and other studies (Lannering et al, 1990), suggests that published incidence figures based on cancer registration may be conservative.…”

Section: Methodssupporting

confidence: 74%

Registration quality and descriptive epidemiology of childhood brain tumours in Scotland 1975-90

McKinney

Ironside²,

Harkness³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

S_nary Children (0-14 years) with malignant brain and central nervous system (CNS) tumours (ICD9 191 and 192) were listed from the Scottish Cancer Registration Scheme for the years 1975-90. These cases formed the basis for validation and verification procedures aimed at providing a complete and accurate data set for epidemiological analyses. A variety of data sources were cross-checked to optimise ascertainment, and resulting from this 5.7% of validated cases were found on the cancer registry with diagnostic codes outside the ICD-9 range [191][192]. A further 8.4% were newly registered cases. Analyses were conducted on the validated data set showing a significant temporal increase in incidence rates over the 16 year study period with an average annual percentage change of + 2.6%. Large-scale geographical heterogeneity was also found, with a particularly high incidence in the Fife and Lothian areas and a low incidence in Grampian. Examination of associations with socioeconomic status, using the Carstairs deprivation index, revealed a rising trend in incidence strongly linked to areas with increasing levels of affluence. Our results suggest that for studies of childhood CNS tumours validation of cancer registry data is necessary and large-scale geographical variation and socioeconomic factors should be taken into account in any investigation of distribution in small geographical areas.Recent technological advances in a range of diagnostic techniques have made the identification of tumours in the brain and central nervous system potentially more complete and accurate. However, temporal trends in the incidence of brain tumours are sparsely documented for children and young people, and international variation shows inconsistent trends (Davis et al., 1990, Mao et al., 1991. Suggested increases in incidence must be interpreted in relation to the impact of improved diagnostic techniques on the ascertainment of cases.As a preliminary to a geographical study investigating the incidence of childhood cancer near nuclear facilities in Scotland, a validation exercise was initiated to provide an optimal data set in terms of completeness and accuracy. This involved cross-checking of alternative sources of ascertainment, validation of diagnosis and verification of case details. As part of this exercise the incidence and pathology of central nervous system (CNS) tumours in children in Scotland between 1975 and have been reviewed.The main source of data for the study was the Scottish National Cancer Registration Scheme (SMR6). The two aims of this paper are to assess the completeness and accuracy of the original cancer registration data for childhood CNS tumours and, for the validated data set, to describe the incidence and broad geographical distribution in Scotland. For each cancer registration and potential new case a form was created showing initial diagnosis and case details and was passed to the collaborating pathologist (J.W.I.). The form was structured in order to permit the pathologists to indicate whether or not a par...

show abstract

Section: Methodssupporting

confidence: 74%

Registration quality and descriptive epidemiology of childhood brain tumours in Scotland 1975-90

McKinney

Ironside²,

Harkness³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, it is well known that, in addition to the neuropathological grade, other factors, such as patient age and gender, type of symptoms at onset and site of location, may affect the prognosis [2,[14][15][16]. As a result, at least some of these factors may lead to overlapping between the different grades in the clinical evolution.…”

Section: Fig 2a-c Same Patient As Inmentioning

confidence: 99%

Supratentorial diffuse astrocytic tumours: proposal of an MRI classification

et al. 1997

View full text Add to dashboard Cite

The aim of this study was to obtain an MRI severity-related classification of diffuse astrocytic tumours able to integrate the histological data in the grading of such tumours. We studied presurgical MR images of 91 patients with a histological diagnosis of astrocytoma, anaplastic astrocytoma and glioblastoma. A score ranging from 1 to 3 was assigned by two independent readers to each of the following MR features: oedema, mass effect, contrast enhancement, borders, signal homogeneity, necrosis, haemorrhage and flow void. Statistical analysis showed significant differences in the mean MRI scores between the three histological grades. Contrast enhancement was found to be the best predictor of the histological grade followed by necrosis, signal homogeneity and border scores. This classification represents a simple and reproducible means of carefully evaluating some macroscopic characteristics of these tumours. It could be used to integrate histological data especially in cases in which tissue sampling defects may affect the validity of this examination.

show abstract

“…Despite multimodal therapies, the median survival time of patients with glioblastoma multiforme is f1 year; however, there is considerable variability among these patients. Prognostic indicators have included age (1,2), Karnofsky performance scale (KPS) score (3), and extent of surgical resection (4,5). The most frequent genetic alteration associated with glioblastoma multiforme is amplification of the epidermal growth factor receptor (EGFR) gene, which results in overexpression of the EGFR, a transmembrane tyrosine kinase receptor (6).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

Heimberger¹,

Hlatky²,

Suki³

et al. 2005

Clinical Cancer Research

465

339

View full text Add to dashboard Cite

Purpose: The epidermal growth factor receptor (EGFR) is overexpressed in f f50% to 60% of glioblastoma multiforme tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases. We sought to determine whether glioblastoma multiforme expression of either overexpressed wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall patient survival.Experimental Design: Glioblastoma multiforme patients (n = 196) underwent a _ > > 95% volumetric tumor resection followed by conformal radiation. Their EGFR and EGFRvIII status was determined by immunohistochemistry and survival analyses were done.Results: In our study of glioblastoma multiforme patients, 46% (n = 91) failed to express EGFR, 54% (n = 105) had overexpression of the wild-type EGFR, and 31% (n = 61) also expressed the EGFRvIII. Patients within groups expressing the EGFR, EGFRvIII, or lacking EGFR expression did not differ in age, sex, Karnofsky performance scale score, extent of tumor resection, or radiation. The median overall survival times for patients with tumors having EGFR expression absent, overexpressed only, or mutant (EGFRvIII) were 0.96, 0.98, and 1.07 years, respectively. However, for patients surviving _ > > 1 year, these values were 2.03, 2.02, and 1.21 years (P < < 0.0001; log-rank test comparing EGFRvIII with all others). This effect remained significant in the multivariate analysis after adjustment for all other cofactors including age and Karnofsky performance scale score (rate ratio 4.34; 95% confidence interval, 2.21-8.51). Conclusions:Neither the overexpressed wild-type EGFR nor EGFRvIII was an independent predictor of median overall survival in this selected cohort of patients who underwent extensive tumor resection. However, in patients surviving _ > > 1 year, the expression of EGFRvIII was an independent negative prognostic indicator.

show abstract

A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984

Cited by 46 publications

References 33 publications

Registration quality and descriptive epidemiology of childhood brain tumours in Scotland 1975-90

Registration quality and descriptive epidemiology of childhood brain tumours in Scotland 1975-90

Supratentorial diffuse astrocytic tumours: proposal of an MRI classification

Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

Contact Info

Product

Resources

About